Daniel de Boer
Chief Executive Officer bei PROQR THERAPEUTICS N.V.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Daniel Anton de Boer is the founder of ProQR Therapeutics NV, PC Basic B.V., and Running It.
He held the position of Chief Executive Officer at each of these companies.
Additionally, he is also the founder of Amylon Therapeutics BV.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PROQR THERAPEUTICS N.V.
0,87% | 31.12.2023 | 705 309 ( 0,87% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Daniel de Boer
| Unternehmen | Position | Beginn |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Chief Executive Officer | 21.02.2012 |
Ehemalige bekannte Positionen von Daniel de Boer
| Unternehmen | Position | Ende |
|---|---|---|
| Running It | Chief Executive Officer | 01.09.2011 |
| PC Basic B.V. | Chief Executive Officer | 01.02.2008 |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Founder | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PROQR THERAPEUTICS N.V. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| PC Basic B.V. | |
| Running It | |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Health Technology |
